ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Birmingham, AL, USA:

FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Enrolling
Multiple Myeloma
Myeloma
Drug: Bendamustine
Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Phase 1

Fate Therapeutics
Fate Therapeutics

Birmingham, Alabama, United States and 13 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Fludarabine
Drug: Bendamustine

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 9 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Birmingham, Alabama, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Birmingham, Alabama, United States and 59 other locations

(CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma.The study will consist of 2 parts: dose-escalation ...

Active, not recruiting
Multiple Myeloma
Biological: CC-98633

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 10 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Birmingham, Alabama, United States and 211 other locations

as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts:...

Active, not recruiting
Multiple Myeloma
Drug: CC-92328

Phase 1

Celgene
Celgene

Birmingham, Alabama, United States and 14 other locations

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

Birmingham, Alabama, United States and 36 other locations

of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: CB-011

Phase 1

Caribou Biosciences

Birmingham, Alabama, United States and 17 other locations

escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: CC-93269

Phase 1

Celgene
Celgene

Birmingham, Alabama, United States and 34 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems